BEIJING, August 15, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (the company) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter financial results for the period ended June 30, 2012. Sinovac is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccine products. The company is making efforts to implement its business strategy to expand its range of product portfolio for both domestic and international markets. The Company has built a solid foundation of commercialized vaccines for hepatitis A, hepatitis A&B and seasonal flu. It has developed specialized pandemic flu vaccines for the H1N1 (swine flu) and H5N1 (avian flu) strains that have been stockpiled by Chinese government. Sinovac also has an extensive human vaccine pipeline inclusive of EV71 and pneumococcal vaccine candidates.
2012 Second Quarter Financial Highlights (year-over-year comparisons to second quarter 2011)
Recent Business Highlights
Dr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "Our financial results for the first half of 2012 clearly demonstrate the management team's progress in executing on our business strategies. We continue to aggressively expand our hepatitis A&B vaccine business in the private pay market, and we believe that we can leverage this experience when we commercialize our EV71 vaccine and other pipeline products in China. Besides strengthening our capability in the private market, we have been making significant efforts to expand our presence in the public market. Recently, we attribute winning the Gansu tender to the development of our public pay market sales initiatives."
Dr. Yin continued, "The Company's increased investment in R&D is driven by our EV71 Phase III trial, which is continuing in line with our targeted schedule. We are pleased to see the progress we have made in this Phase III clinical trial. The healthcare professionals participating in the trial are actively collecting the required data based on the quality and quantity specified in the protocol for the efficacy analysis of the vaccine candidate. In parallel with the clinical trial, the preparation of our dedicated EV71 vaccine production plant is underway. We anticipate that once the clinical trial is completed and after SFDA approval is obtained, we can immediately apply for the GMP certification for the plant, and make sure the EV71 vaccine product can be launched into the market without delay."
Dr. Yin continued, "We are on track to receive the GMP certification for our mumps vaccine. We are very pleased to see that after more than two years of development, Sinovac Dalian's first product is expected to be launched into the market in the coming months. This product will be the first mumps vaccine launched domestically which is manufactured in the plant that is in compliance with the new GMP standards in China."
Dr. Yin concluded, "Our strong cash position and secured credit line with a local commercial bank ensure our short-term investment needs on pipeline product development and facilities to drive the short-term and medium-term growth."
Financial Review for Second Quarter Ended June 30, 2012
An analysis of sales and gross profit is as follows:
In USD | 2012Q2 | % of Sales | 2011Q2 | % of Sales | YOY Quarterly Growth % |
Hepatitis A - Healive | 3,560,852 | 38.0% | 3,274,432 | 20.9% | 8.7% |
Hepatitis A&B - Bilive | 6,069,575 | 64.8% | 4,823,509 | 30.8% | 25.8% |
Hepatitis vaccines | 9,630,427 | 102.8% | 8,097,941 | 51.7% | 18.9% |
Influenza vaccines | -267,677 | -2.8% | -135,069 | -0.8% | |
Animal vaccine | 1,882 | ||||
Core sales | 9,364,632 | 100% | 7,962,872 | 50.9% | 17.6% |
H5N1 | - | - | 7,693,227 | 49.1% | |
Total Sales | 9,364,632 | 100% | 15,656,099 | 100% | -40.2% |
Cost of sales | 1,375,917 | 14.7% | 4,877,963 | 31.2% | |
Gross Profit | 7,988,715 | 85.3% | 10,778,136 | 68.8% |
Core vaccine sales in the second quarter of 2012 increased 17.6% to $9.4 million, compared to $8.0 million in the same period of 2011. Bilive vaccines sales were up 25.8% this quarter. Total sales decreased 40.2%, compared to $15.7 million in the same period of last year that included $7.7 million of non-core government stockpile pandemic flu H5N1 vaccine sales.
Gross profit margin of the core sales was 85.3%, compared to 84.2% in the same period of last year. The overall gross profit margin for the same period in 2011 was 68.8% since the prior year quarter included a substantial proportion of non-core H5N1 vaccine sales that carried a lower gross margin. After deducting depreciation of land use rights, amortization of licenses and permits, the respective overall gross margins were 84.8% and 67.9% for the second quarters of 2012 and 2011.
Selling, general and administrative expenses for the second quarter 2012 were $6.7 million, compared to $5.0 million in the same period of 2011. SG&A expenses as a percentage of second quarter 2012 sales were 71.6%, compared to 31.8% during the second quarter of the prior year. Excluding the pandemic flu H5N1 vaccine sales in prior year quarter, SG&A expenses as a percentage of sales were 71.6% and 62.5% for the current quarter and prior year quarter respectively. The increased SG&A expenses was mainly due to the increased spending on sales and marketing programs to penetrate the private-pay market, preparation costs for GMP upgrade, and validation efforts for the equipment at Changping site that began in 2012.
Research and development expenses for the second quarter reached $4.7 million, a $2.4 million increase over the same period in 2011, mainly due to the ongoing EV71 Phase III clinical trial. The increase in research and development expenses in the second quarter over last year quarter was in line with the continued progress of the various research and development initiatives intended to drive the Company's pipeline products towards commercialization.
Depreciation of property, plant and equipment and amortization of licenses and permits for second quarter 2012 was $0.3 million, compared to $0.5 million for the same period of last year. The lower depreciation and amortization expenses in the second quarter of 2012 was mainly benefited from lower amortization expenses arising from fully amortized license and permits for the inactivated hepatitis A vaccine,
Total operating expenses for the second quarter 2012 were $10.3 million, compared to $7.6 million for the same quarter last year. The major drivers of the higher operating expense were the increased research and development expenses as the Company advances its pipeline vaccine candidates, and increased SG&A expenses due to more spending for core vaccines sales after offsetting from additional government grants recognized in income.
The Company's operating loss was $2.3 million for the second quarter 2012, compared to $3.1 million operating income for the same quarter last year. The swing from operating income in the last year's quarter to operating loss in this year's quarter was mainly due to the loss of the prior year contribution from government stockpile H5N1 vaccine sales of $7.7 million and the $2.7 million change in operating expenses discussed above.
Loss before income taxes and non-controlling interests was $2.0 million, compared to the net income $3.4 million in the same quarter last year.
Net loss attributable to stockholders in the second quarter 2012 was $0.9 million, or $0.02 per basic and diluted share, compared to a net income of $1.3 million, or $0.02 per basic and diluted share, for the same quarter last year.
As of June 30, 2012, cash and cash equivalents totaled $89.4 million, compared to $94.5 million as of March 31, 2012 and $104.3 million as of December 31, 2011, respectively. The Company utilized $2.3 million and $5.4 million of its cash resources in the second quarter and first six months period, respectively, for its ongoing clinical trial for its proprietary EV71 vaccine. The Company intends to allocate approximately an additional $3.7 million during the second half of 2012 and $0.9 million in 2013 to fund the ongoing Phase III trial. Under the credit line arrangements already in place that cover the ongoing capital needs of the Changping site development, $2.8 million was utilized in the second quarter, with $5.0 million utilized during the first half of the year. Capital expenditure payments to complete the Changping site, which are covered by the same credit line arrangements, are estimated at$17.2 million in the remaining quarters of 2012 and $1.7 million in 2013.
Financial Review for the Six Months Period Ended June 30, 2012
An analysis of sales and gross profit is as follows:
In USD | 2012 1st Half Year | % of sales | 2011 1st Half Year | %of sales | YOY 1st Half Year Growth |
Hepatitis A - Healive | 5,172,428 | 33.7% | 5,651,233 | 27.8% | -8.5% |
Hepatitis A&B - Bilive | 10,085,035 | 65.8% | 6,910,891 | 34.0% | 45.9% |
Hepatitis vaccines | 15,257,463 | 99.5% | 12,562,124 | 61.8% | 21.5% |
Influenza vaccines | 46,407 | 0.3% | 81,340 | 0.4% | -42.9% |
Animal vaccine | 34,229 | 0.2% | |||
Core Sales | 15,338,099 | 100% | 12,643,464 | 62.2% | 21.3% |
H5N1 | - | - | 7,693,227 | 37.8% | |
Total Sales | 15,338,099 | 100% | 20,336,691 | 100% | -24.6% |
Cost of sales | 3,631,206 | 23.7% | 6,463,980 | 31.8% | |
Gross Profit | 11,706,893 | 76.3% | 13,872,711 | 68.2% |
Core vaccines sales of the first six months period of 2012 increased 21.3% to $15.3 million, compared to $12.6 million in the same period of 2011. Bilive vaccines sales were up 45.9% during the first six months of 2012. Total sales decreased 24.6% to $15.3 million, compared to $20.3 million in the same period of last year, in which there was non-core government stockpile pandemic flu H5N1 vaccine sales of $7.7 million.
Gross profit margin of the core sales for the first six month period of 2012 was 76.3%, compared to the 77.5% in the same period of last year. The overall gross profit margin of the same period in 2011 was 68.2%. After deducting depreciation of land use rights, amortization of licenses and permits, the overall gross margin was 75.9% and 66.9% for the first six months period of 2012 and 2011, respectively.
Selling, general and administrative expenses for the first six months period of 2012 were $11.0 million, compared to $9.1 million in the same period of 2011. SG&A expenses as a percentage of the 2012 first six months period sales was 71.9%, compared to 44.7% in the same period of 2011. Excluding the pandemic flu H5N1 vaccine sales in first six month of 2011, the SG&A expenses as a percentage of sales was 71.9% for both the first six months period of 2012 and 2011.
Research and development expenses for the first six months period of 2012 reached $12.0 million, a $7.6 million increase over the same period in 2011 which was mainly because of the ongoing EV71 clinical trial.
Depreciation of property, plant and equipment and amortization of licenses and permits for the first six months period of 2012 was $0.6 million, compared to $0.8 million for the same period last year.
Total operating expenses for the first six months period of 2012 were $22.2 million, compared to $14.2 million for the same period last year. The major drivers of the higher operating expense were the increased research and development expenses as the Company advances its pipeline vaccine candidates and increased SG&A expenses due to more spending for core vaccines sales after offsetting from additional government grants.
The Company's operating loss was $10.5 million for the first six months period of 2012, compared to $0.3 million operating loss for the same period of last year.
Loss before income taxes and non-controlling interests was $9.7 million, compared to the net loss of $1,484 in the same period last year.
Net loss attributable to stockholders in the first six months period of 2012 was $6.5 million, or $0.12 per basic and diluted share, compared to a net loss of $1.5 million, or $0.03 per basic and diluted share, for the same period last year.
Conference Call Details
The Company will host a conference call on Wednesday, August 15, 2012 at 8:00 a.m. EDT (August 15, 2012 at 8:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate developments. To access the conference call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (International). A replay of the call will be available from 11 a.m. EDT on August 15, 2012 to August 29, 2012 at midnight. To access the replay, please dial 1-877-870-5176 (USA) or 1-858-384-5517 (International) and reference the replay pin number 398683.
A live audio webcast of the call will also be available from the investors section on the corporate web site at www.sinovac.com. A webcast replay can be accessed on the corporate website beginning August 15, 2012 and the replay will remain available for 30 days.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu) and H1N1 influenza (swine flu), as well as animal rabies vaccine for canines. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, Panflu.1, and has manufactured it for the Chinese Central Government, pursuant to the government-stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government-stockpiling program. Sinovac is developing a number of new pipeline vaccines including vaccines for enterovirus 71 (against hand, foot and mouth disease), pneumococcal conjugate, pneumococcal polysaccharides, mumps and rubella. Sinovac sells its vaccines mainly in China and exports selected vaccines to Mongolia, Nepal, and the Philippines.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
Helen Yang/Chris Lee
Sinovac Biotech Ltd.
Tel: +86-10-8279-9871/9659
Fax: +86-10-6296-6910
Email: ir@sinovac.com
Investors:
Stephanie Carrington
The Ruth Group
Tel: +1-646-536-7017
Email: scarrington@theruthgroup.com
Media:
Victoria Aguiar
The Ruth Group
Tel: +1-646-536-7013
Email: vaguiar@theruthgroup.com
SINOVAC BIOTECH LTD. | ||||
Incorporated in Antigua and Barbuda | ||||
Consolidated Balance Sheets | ||||
(Unaudited) | ||||
(Expressed in U.S. Dollars) | ||||
30-Jun-12 | 31-Dec-11 | |||
ASSETS | ||||
Current assets | ||||
Cash and cash equivalents | $ | 89,440,373 | $ | 104,286,695 |
Accounts receivable - net | 18,533,886 | 17,834,407 | ||
Inventories | 14,226,557 | 8,113,428 | ||
Prepaid expenses and deposits | 1,408,762 | 1,804,555 | ||
Total current assets | 123,609,578 | 132,039,085 | ||
Property, plant and equipment | 80,961,440 | 75,627,881 | ||
Long-term inventories | 3,974,552 | 5,248,237 | ||
Long-term prepaid expenses | 343,374 | 408,656 | ||
Prepayments for acquisition of equipment | 452,144 | 828,902 | ||
Deferred tax assets | 353,903 | 419,114 | ||
Licenses and permits | 1,278,421 | 1,336,254 | ||
Total assets | $ | 210,973,412 | $ | 215,908,129 |
LIABILITIES AND EQUITY | ||||
Current liabilities | ||||
Loans payable | $ | 4,722,178 | $ | 4,713,498 |
Accounts payable and accrued liabilities | 28,698,963 | 29,522,495 | ||
Income tax payable | 234,156 | 3,351,127 | ||
Deferred revenue | 3,794,136 | 429,416 | ||
Dividends payable | - | 795,106 | ||
Deferred government grants | 100,897 | 1,830,566 | ||
Total current liabilities | 37,550,330 | 40,642,208 | ||
Deferred government grants | 2,805,528 | 2,277,428 | ||
Loans payable | 23,330,072 | 17,321,327 | ||
Due to related party | 3,167,008 | - | ||
Deferred revenue | 6,925,862 | 10,369,695 | ||
Total long term liabilities | 36,228,470 | 29,968,450 | ||
Total liabilities | 73,778,800 | 70,610,658 | ||
Commitments and contingencies | ||||
EQUITY | ||||
Preferred stock | - | - | ||
Authorized 50,000,000 shares at par value of $0.001 each | ||||
Issued and outstanding: nil | ||||
Common stock | 55,020 | 54,774 | ||
Authorized: 100,000,000 shares at par value of $0.001 each | ||||
Issued and outstanding: 55,019,861 (2011 -54,773,961) | ||||
Additional paid-in capital | 106,032,906 | 105,383,346 | ||
Accumulated other comprehensive income | 10,113,926 | 9,978,325 | ||
Statutory surplus reserves | 11,808,271 | 11,808,271 | ||
Retained earnings(accumulated deficit) | -3,838,457 | 2,696,227 | ||
Total stockholders' equity | 124,171,666 | 129,920,943 | ||
Non-controlling interests | 13,022,946 | 15,376,528 | ||
Total equity | 137,194,612 | 145,297,471 | ||
Total liabilities and equity | $ | 210,973,412 | $ | 215,908,129 |
SINOVAC BIOTECH LTD. | ||||||||||
Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) | ||||||||||
Three and Six Months Ended June 30, 2012 and 2011 | ||||||||||
(Unaudited) | ||||||||||
(Expressed in U.S. Dollars) | ||||||||||
Three months ended | Six months ended | |||||||||
30-Jun | 30-Jun | |||||||||
2012 | 2011 | 2012 | 2011 | |||||||
Sales | $ | 9,364,632 | $ | 15,656,099 | $ | 15,338,099 | $ | 20,336,691 | ||
Cost of sales - (exclusive of depreciation of land-use rights and amortization of licenses and permits of $46,606 (2011 - $142,123) for three months and $71,970 (2011 -$266,104) for six months) | 1,375,917 | 4,877,963 | 3,631,206 | 6,463,980 | ||||||
Gross profit | 7,988,715 | 10,778,136 | 11,706,893 | 13,872,711 | ||||||
Selling, general and administrative expenses | 6,700,526 | 4,978,973 | 11,020,815 | 9,086,305 | ||||||
Research and development expenses - net of | 4,676,703 | 2,275,639 | 12,018,875 | 4,378,020 | ||||||
$nil (2011- $(142,041)) for three months and $nil (2011- $(215,431)) for six months in government research grants | ||||||||||
Depreciation of property, plant and equipment and amortization of licenses and permits | 324,944 | 461,973 | 632,387 | 846,155 | ||||||
Government grants recognized in income | -1,386,126 | -68,965 | -1,457,330 | -137,447 | ||||||
Total operating expenses | 10,316,047 | 7,647,620 | 22,214,747 | 14,173,033 | ||||||
Operating income (loss) | -2,327,332 | 3,130,516 | -10,507,854 | -300,322 | ||||||
Interest income | 498,856 | 510,087 | 1,096,527 | 655,461 | ||||||
Interest and financing expenses | -232,078 | -342,813 | -446,398 | -412,510 | ||||||
Gain on disposal of equipment | - | 41,210 | - | 33,506 | ||||||
Other income | 14,635 | 13,770 | 132,713 | 22,381 | ||||||
Income (loss) before income taxes and non-controlling interests | -2,045,919 | 3,352,770 | -9,725,012 | -1,484 | ||||||
Income tax recovery (expenses) | 797,462 | -1,475,071 | 800,364 | -1,785,493 | ||||||
Consolidated net income (loss) | -1,248,457 | 1,877,699 | -8,924,648 | -1,786,977 | ||||||
Less: income (loss) attributable to non-controlling interests | -326,828 | 554,057 | -2,389,964 | -315,663 | ||||||
$ | -921,629 | $ | 1,323,642 | $ | -6,534,684 | $ | -1,471,314 | |||
Net income (loss) attributable to stockholders | ||||||||||
Net income (loss) | $ | -1,248,457 | $ | 1,877,699 | $ | -8,924,648 | $ | -1,786,977 | ||
Other comprehensive income (loss) | ||||||||||
Foreign currency translation adjustment | -474,801 | 1,172,742 | 171,982 | 2,012,310 | ||||||
Total comprehensive income (loss) | -1,723,258 | 3,050,441 | -8,752,666 | 225,333 | ||||||
Less: comprehensive income (loss) attributable to non-controlling interests | -373,994 | 725,100 | -2,353,583 | -3,375 | ||||||
Comprehensive income(loss) attributable to stockholders | $ | -1,349,264 | $ | 2,325,341 | $ | -6,399,083 | $ | 228,708 | ||
Basic and diluted earnings (loss) per share | $ | -0.02 | $ | 0.02 | $ | -0.12 | $ | -0.03 | ||
Weighted average number of shares | ||||||||||
of common stock outstanding | ||||||||||
- Basic | 54,804,498 | 54,572,164 | 54,784,801 | 54,509,600 | ||||||
- Diluted | 54,804,498 | 54,572,164 | 54,784,801 | 54,509,600 | ||||||
SINOVAC BIOTECH LTD. | |||||||||
Consolidated Statements of Cash Flows | |||||||||
Three and Six Months Ended June 30, 2012 and 2011 | |||||||||
(Unaudited) | |||||||||
(Expressed in U.S. Dollars) | |||||||||
Three Months ended June 30 | Six Months ended June 30 | ||||||||
2012 | 2011 | 2012 | 2011 | ||||||
Cash flows from (used in) operating activities | |||||||||
Net income(loss) for the period | $ | -1,248,457 | $ | 1,877,699 | $ | -8,924,648 | -1,786,977 | ||
Adjustments to reconcile net income (loss) to net cash from | |||||||||
(used by) operating activities: | |||||||||
- deferred income taxes | 69,231 | 1,460,463 | 66,329 | 1,770,885 | |||||
- write-off of equipment and loss (gain) on disposal | 2,460 | -41,210 | 2,460 | -33,506 | |||||
- unrealized foreign exchange gain | 166,701 | - | -43,880 | - | |||||
- stock-based compensation | 173,791 | 67,971 | 253,966 | 100,633 | |||||
- inventory provision | 1,239,399 | - | 1,325,263 | - | |||||
- depreciation of property, plant and equipment, and amortization of licenses and permits | 1,305,653 | 1,399,348 | 2,558,203 | 2,592,054 | |||||
- research and development expenditures qualifying for government grant | - | -142,041 | -79,113 | -215,431 | |||||
- deferred government grant recognized in income | -1,307,009 | -68,965 | -1,378,213 | -137,447 | |||||
- accretion expenses | 68,398 | 102,564 | 136,789 | 204,409 | |||||
- accounts receivable | 614,574 | 4,330,944 | -671,232 | 4,377,521 | |||||
- inventories | -4,845,918 | -345,299 | -6,165,393 | -2,626,987 | |||||
- income tax payable | -3,136,687 | -402,540 | -3,124,477 | -505,933 | |||||
- prepaid expenses and deposits | -293,778 | -501,030 | 488,378 | -511,790 | |||||
- deferred revenue and advances | |||||||||
from customers | -5 | -3,014,970 | -99,522 | -3,317,650 | |||||
- accounts payable and accrued liabilities | 882,535 | -1,308,444 | -2,522,275 | -4,186,558 | |||||
Net cash provided by (used in) operating activities | -6,309,112 | 3,414,490 | -18,177,365 | -4,276,777 | |||||
Cash flows from (used in) financing activities | |||||||||
- Loan proceeds | 3,985,568 | 1,881,372 | 6,009,507 | 1,881,372 | |||||
- Loan repayment | - | -1,374,424 | - | -1,374,424 | |||||
- Proceeds from issuance of common stock | 343,040 | 251,839 | 393,440 | 536,548 | |||||
- Repayment from non-controlling shareholder of Sinovac Beijing | - | - | - | 3,397,522 | |||||
- Subscriptions received | 2,400 | 8,480 | 2,400 | 8,480 | |||||
- Dividends paid to non-controlling shareholder of | - | - | -800,717 | -5,862,676 | |||||
Sinovac Beijing | |||||||||
- Loan from non-controlling shareholder of Sinovac Dalian | - | - | 3,175,266 | - | |||||
- Government grant received | 240,580 | 7,636 | 240,580 | 7,636 | |||||
Net cash provided by (used in) financing activities | 4,571,588 | 774,903 | 9,020,476 | -1,405,542 | |||||
Cash flows used in investing activities | |||||||||
- Proceeds from redemption of short-term investments | - | 1,547,030.00 | - | 1,547,030.00 | |||||
- Purchase of short-term investments | - | -22,431,931.00 | - | -22,431,931.00 | |||||
- Acquisition of property, plant and equipment | -3,659,160.00 | -4,544,793.00 | -6,619,621.00 | -5,698,141.00 | |||||
Net cash used in investing activities | -3,659,160.00 | -25,429,694.00 | -6,619,621.00 | -26,583,042.00 | |||||
Exchange effect on cash and cash equivalents | 347,410 | 559,552 | 930,188 | 967,151 | |||||
Increase (decrease) in cash and cash equivalents | -5,049,274 | -20,680,749 | -14,846,322 | -31,298,210 | |||||
Cash and cash equivalents, beginning of period | 94,489,647 | 90,968,029 | 104,286,695 | 101,585,490 | |||||
Cash and cash equivalents, end of period | $ | 89,440,373 | $ | 70,287,280 | $ | 89,440,373 | 70,287,280 | ||
Cash paid for interest | $ | 231,563 | $ | 356,085 | $ | 477,639 | 641,420 | ||
Cash paid for income taxes | $ | $ | 417,148 | $ | - | 520,514 | |||
Supplemental schedule of non-cash activities: | |||||||||
Acquisition of property, plant and equipment included in | |||||||||
accounts payable and accrued liabilities | 9,962,278 | $ | 3,625,631 | $ | 9,962,278 | 3,625,631 | |||
